The first participant has been randomized in the PRECISE-HD Confirmatory study of Pridopidine.

Ferrer and Prilenia are pleased to update you that the first participant has been randomized in the PRECISE-HD confirmatory Phase 3 study of pridopidine, an investigational medicinal product taken as an oral capsule twice daily, in Huntington’s disease (HD).

This milestone marks the start of participant enrolment, with several US sites now active and additional sites in Canada, the EU and the UK set to follow later this year.

PRECISE-HD is designed to further evaluate the efficacy and safety of pridopidine and generate data to support regulatory evaluation. The approximately 400-participant, randomized, double-blind, placebo-controlled study will assess the effects of pridopidine on a range of clinical and functional outcomes relevant to Huntington’s disease.

Updated information on the study and open sites is available on CT/Trials: NCT07609108.